In nonalcoholic fatty liver disease (NAFLD)-associated HCC, cancer cells show an elevated expression of N6-methyladenosine (m6A)-methyltransferase catalytic subunit (METTL3). Here, METTL3 is linked to metabolic dysfunction-associated steatotic liver disease.